Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Unregistered Sales of Equity Securities

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities.

Story continues below

On August 1, 2017, the Company sold to an unaffiliated investor 5.0 million shares of its common stock at a price of $0.20 per share and issued to such investor 2.5 million Class D Warrants exercisable at $0.23 per share for a period of two years, and 2.5 million Class D Warrants exercisable at $0.30 per share for a period of two years, for an aggregate of $1.0 million.

The securities were issued to the exemption from the registration requirements afforded by Section 4(a)(2) and Regulation D of the Securities Act.


About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

An ad to help with our costs